Alembic Pharmaceuticals receives tentative approval for Febuxostat Tablets

From USFDA

Alembic Pharmaceuticals announced that it has received tentative approval from the USFDA for its ANDA for Febuxostat Tablets, 40 mg and 80 mg. The approved ANDA is the therapeutically equivalent to the reference listed drug product Uloric Tablet, 40 mg and 80 mg of Takeda Pharmaceuticals USA, Inc.

Powered by Capital Market - Live News